Cosentyx® (secukinumab)

Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active moderate to severe hidradenitis suppurativa (HS; acne inversa) in adults with an inadequate response to conventional systemic HS therapy; active enthesitis-related arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.¹

Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated.¹

In Ireland Cosentyx is reimbursed for the following indications: adult plaque psoriasis (PsO); psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).

Please refer to the Summary of Product Characteristics (SmPC) for full prescribing information and safety profile.¹

For your eligible PsO patients

All images are of fictional patients and healthcare practitioners

SKIN CLEARANCE is meant by: 69% Psoriasis Area and Severity Index (PASI) 100, an exploratory endpoint, achieved in PsO patients receiving Cosentyx  300 mg (n=80) vs 22.4% of patients receiving narrowband ultraviolet B (nb-UVB) phototherapy (n=80) (p<0.0001) through Week 52. The primary endpoint of PASI 90 response at week 52 for Cosentyx 300 mg vs nb-UVB was met (91.1% vs 42.3% respectively, p<0.0001).²
FURTHER is meant by: 90% of PsO patients with PsA (n=222 ) taking Cosentyx 300 mg showed no radiographic progression through Year 2 (observational data, no statistical testing). The primary endpoint of proportion of patients achieving ACR20 response at Week 16 was met (Cosentyx 300 mg 62.6% vs placebo 27.4%, p<0.0001).^3,4

Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated. Please refer to the Cosentyx SmPC for full product information before prescribing.¹

Cosentyx is to be administered by subcutaneous injection. Patients may self-inject Cosentyx, if properly trained and considered appropriate by the physician.¹

Please refer to the SmPC for full details on method of administration.

ACR, American College of Rheumatology; AS, ankylosing spondylitis; axSpA, non-radiographic axial spondyloarthritis; ERA, enthesitis-related arthritis; HCP, healthcare professional; HS, hidradenitis suppurativa; JPsA, juvenile psoriatic arthritis; MTX, methotrexate; nb-UVB, narrowband ultraviolet B; nr-axSpA, non-radiographic axial spondyloarthritis; PASI, psoriatic area and severity index; PsA, psoriatic arthritis; PsO, plaque psoriasis; SPC, Summary of Product Characteristics.

References

1. Cosentyx® (secukinumab) Summary of Product Characteristics. Available at: www.medicine.ie.

2. Iversen L, et al. J Eur Acad Dermatol Venereol 2023;37(5):1004–1016.

3. Mease PJ, et al. RMD Open 2021;7(2):e001600.

4. Mease P, et al. Ann Rheum Dis 2018;77(6):890–897.

IE11490991 | March 2026